Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.

OBJECTIVE:Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treatment of diabetes. We aimed at describing the maximal benefits and risks associated with SGLT2-i for patients with type 2 diabetes. DESIGN:Systematic review and meta-analysis. DATA SOURCES AND STUDY SEL...

Full description

Bibliographic Details
Main Authors:	Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2016-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5106000?pdf=render

Similar Items

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
by: Munteanu Madalina Andreea, et al.
Published: (2023-04-01)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
by: Vijaya Subramanian, et al.
Published: (2022-09-01)

A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease
by: Anders Ellekær Junker, et al.
Published: (2014-12-01)

Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes.
by: Andrea Mari, et al.
Published: (2013-01-01)

The effect of exogenous glucagon on circulating amino acids in individuals with and without type 2 diabetes and obesity
by: Magnus F G Grøndahl, et al.
Published: (2024-02-01)

Accuracy of continuous glucose monitoring during exercise-related hypoglycemia in individuals with type 1 diabetes
by: Kaisar Maytham, et al.
Published: (2024-04-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
by: Habib Yaribeygi, et al.
Published: (2023-04-01)

Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial
by: Tina Vilsbøll, et al.
Published: (2023-02-01)

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
by: Siarhei A. Dabravolski, et al.
Published: (2022-05-01)

Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control
by: Manash Pratim Baruah, et al.
Published: (2019-01-01)

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
by: Boyang Xiang, et al.
Published: (2021-04-01)

Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis
by: Jan P. Kleinjan, et al.
Published: (2024-03-01)

Protocol for assessing the effects of exogenous hormone administration on human postprandial glucose metabolism, appetite sensations, and food intake
by: Christoffer A. Hagemann, et al.
Published: (2023-03-01)

Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes
by: Amelia K. Fotheringham, et al.
Published: (2020-09-01)

Lowering the risk of gout: Another benefits from the use of sodium–glucose cotransporter 2 inhibitors
by: Wayne H‐H Sheu
Published: (2020-09-01)

Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Hypoglycaemia and cardiac arrhythmias in diabetes
by: Andreas Andersen, et al.
Published: (2020-05-01)

How glucagon-like peptide 1 receptor agonists work
by: Christine Rode Andreasen, et al.
Published: (2021-07-01)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022-02-01)

Incidental finding of non-alcoholic steatohepatitis-cirrhosis
by: Therese Adrian, et al.
Published: (2022-01-01)

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
by: A. M. Mkrtumyan, et al.
Published: (2021-09-01)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions
by: Habib Yaribeygi, et al.
Published: (2023-01-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
by: Xiaoya Sun, et al.
Published: (2022-12-01)

Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia
by: Jordi Real, et al.
Published: (2021-07-01)

Benefits and harms of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐I) and renin–angiotensin–aldosterone system inhibitors (RAAS‐I) versus SGLT2‐Is alone in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
by: Samuel Seidu, et al.
Published: (2022-01-01)

An exanthematous drug eruption with sodium‐glucose cotransporter 2 inhibitor
by: Ryu Fukase, et al.
Published: (2024-01-01)

Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
by: Jiangjun Wei, et al.
Published: (2023-04-01)

The Rate of Adverse Events of Sodium-Glucose Cotransporter 2 Inhibitors:
by: Omar Sajdeya
Published: (2023-05-01)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
by: He Sun, et al.
Published: (2023-01-01)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
by: Fan Yang, et al.
Published: (2020-12-01)

Medication counselling with sodium glucose transporter 2 inhibitor therapy
by: Sanjay Kalra, et al.
Published: (2014-01-01)

Supportive and non-supportive interactions in families with a type 2 diabetes patient: an integrative review
by: Birgitte B. Bennich, et al.
Published: (2017-07-01)

Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice
by: Arturo Cesaro, et al.
Published: (2023-04-01)

Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis
by: Xiehui Chen, et al.
Published: (2022-12-01)

Effectiveness and safety of sodium–glucose cotransporter 2 inhibitors in Asian populations
by: Kyoung Hwa Ha, et al.
Published: (2024-03-01)

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
by: Hidekatsu Yanai, et al.
Published: (2021-04-01)

Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
by: Victor Chien-Chia Wu, et al.
Published: (2021-07-01)